Sign in to your account

Reset your password

Enter your doctor ID to get a reset code, then choose a new password.

Don't have an account?
Register as new doctor
A Doctor ID will be generated for you. Your default password is "password", change it after first login.
✓ Account created Your generated Doctor ID:
DR-XXXX
Default password: password
--
Settings
Sign out
Hospital
Tumour board and registered care teams
Registered doctors
--
Settings
Sign out
My Patients
Click any patient ID to open their full oncology dashboard
--
Sign out
Settings
Account preferences and security
Account
Doctor ID,
Name,
Email,
Specialty,
Change password
✓ Password updated
ONCORA
Oncology Intelligence Platform
Powered by Synergenix AI
3
RP
DR-1001
/ Hospital › My Patients › PT-490001
AB
PT-490001
MRN: 4820195 Female · 52 yrs · DOB: 14 Mar 1972 Enrolled: 02 Jan 2026 DR-1001 · Medical Oncology Ward B2 · Room 214 ICD-10: C22.0
Hepatocellular carcinoma BCLC A Atezolizumab + Bevacizumab PR −42% (RECIST 1.1) ANC ↓ Grade 3
Patient Summary Report
,
Describe the case
Every tab below is predicted from what you enter here. Type it, or upload a report.
Case loaded
,
Feeding all tabs
Dashboard
Tumour size projected forward under this treatment, and what the environment adds to it.

Model inputs

Environmental exposure Xenv
Tap a source to include it. Tap again to change how heavy it is.
Clinical report intake
Prescription intake
Tumour size over time: with vs without treatment
size (mm)
How this patient compares with typical cases
slow-growing · typical · fast-growing, with this patient overlaid
Recommended plan: how the drug test and tumour biology combine
decision-support only
What this means
in plain language
Select a patient to load server metrics.
Tumour Response · RECIST 1.1
Target lesions · server time-series
Live data
0
CR (≤−100%)
✓ 1
PR (≤−30%)
0
SD (−30% to +20%)
0
PD (≥+20%)
Loading RECIST from server…
Scroll to zoom · drag to pan · double-click to reset
Tumour Markers, Longitudinal
Tumour markers · live server feed
,
CBC / Haematology, Trend
CBC trend · live server feed
,
Scroll to zoom · drag to pan
Active Treatment Protocol
Loading regimen…
,
Select a patient to load disease-specific treatment.
Adverse Events · CTCAE v5.0
Current cycle toxicity profile · NCI MedDRA coded
3 Active · Grade ≥2
Adverse Event MedDRA Grade (CTCAE) Management
Select a patient
Molecular & Biomarker Profile
IHC · FISH · NGS (FoundationOne CDx Panel) · Baseline biopsy
NGS Complete
Select a patient to load molecular profile.
Performance Status
Stable
1
ECOG, Restricted / Ambulatory
Restricted in physically strenuous activity but ambulatory and able to carry out light or sedentary work. Normal activity with effort, some signs of disease.
0, Fully Active 4, Bedridden
Karnofsky Performance Scale (KPS)
80%
Normal activity with effort
Some signs / symptoms of disease
Model Drivers
Server
Open a patient to see prediction drivers.
Oncora Oncology Intelligence Platform · v3.2.1  |  HL7 FHIR R4 Compliant · HIPAA / GDPR Compliant · For Authorised Clinical Use Only  |  ICD-10-CM · TNM 8th Ed. (AJCC/UICC) · CTCAE v5.0 · RECIST 1.1 · NCCN Guidelines v2025 · WHO Classification of Tumours
Trends & Analytics
What happens over time: tumour size, marker levels and blood counts projected forward from the case.
RECIST 1.1, Tumour Response Waterfall
Change from baseline · Target lesions · Best overall response
,
Tumour Markers Over Time
Model
CBC Nadir Trend
ANC, Haemoglobin & Platelets per cycle
,
Cardiac Function, LVEF
Echocardiogram and blood pressure, bevacizumab surveillance
Stable
Body Weight & BMI Trend
Nutritional status across cycles · BSA recalculation trigger if Δ>10%
−3.2 kg
Hepatic Function, ALT / AST
Liver enzyme monitoring · Docetaxel hepatotoxicity surveillance
WNL
Pathology Report
The tissue picture implied by the case: grade, proliferation and stains. Derived from the growth figures, not from a slide.
Genomics & Molecular Profile
The mutations this presentation and exposure history most likely carry. An expectation to test, not a sequencing result.
Predictive Layer
How fast this tumour grows and how well it should answer treatment, worked out from the growth figures.
Pharmaceuticals
Which drug this tumour should answer best, at what dose, and how a prescription you type scores against it.
No patient loaded
Open a patient from My Patients to see their pharmaceutical orders.
Radiation Oncology
A radiotherapy plan for this lesion: dose, fractions and margins. A template for the tumour board, not a prescription.
No case loaded
Open the Dashboard, describe or pick a case, and the radiotherapy plan is generated for the tumour site.
Clinical State Prediction
Where the patient stands today, and where this treatment takes them.
No clinical state inferred yet
Describe or pick a case above, Synergenix fuses the inputs into a time-aware patient state and projects its future under the recommended action.
Early Detection
How many mutation routes this tumour has opened, how much traces to the environment, and whether it is visible to the immune system.
Imaging
Lesion dimensions on CT or MRI, measured today and projected forward on this treatment.
Case Detail
Everything the model derives from this case, in the order a tumour board works through it.
Clinical Records
The case written up as notes: diagnosis, tumour board decision and response assessment.
Recent Progress Notes
Select a patient to load notes.
Lab Trends, Server + Model
TestBaselineLatestSource
Select a patient